João R L C B Maia, Loreena K A Machado, Gabriel G Fernandes, Louise C Vitorino, Letícia S Antônio, Suzana Maria B Araújo, Lilian C Colodeti, Fabrícia L Fontes-Dantas, Julianna D Zeidler, Georgia N Saraiva, Andrea T Da Poian, Claudia P Figueiredo, Giselle F Passos, Robson da Costa
Oxaliplatin (OXA) is an antineoplastic agent used for the treatment of cisplatin-resistant tumours, presenting lower incidence of nephrotoxicity and myelotoxicity than other platinum-based drugs. However, OXA treatment is highly associated with painful peripheral neuropathy, a well-known and relevant side effect caused by mitochondrial dysfunction. The transfer of functional exogenous mitochondria (mitotherapy) is a promising therapeutic strategy for mitochondrial diseases. We investigated the effect of mitotherapy on oxaliplatin-induced painful peripheral neuropathy (OIPN) in male mice...
December 27, 2023: Neuropharmacology